You are here

lung cancer

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

Pharmaforum

colorectal cancer

Flag link:

AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead

AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead

Motley Fool

Flag link:

AstraZeneca bid to expand lung cancer drug's use boosted by trial data

AstraZeneca bid to expand lung cancer drug's use boosted by trial data

BioPharma Dive

clinical trials

Flag link:

3 Roche Companies Hope to Make Clinical Trials More Efficient

3 Roche Companies Hope to Make Clinical Trials More Efficient

Medical Devices and Diagnostics Industry

Flatiron Health

Foundation Medicine

clinical trials

Flag link:

AstraZeneca to unveil key data for cancer drugs at ASCO

AstraZeneca to unveil key data for cancer drugs at ASCO

Pharmaforum

colorectal cancer

Flag link:

ASCO 2020 – first-line lung cancer focus

ASCO 2020 – first-line lung cancer focus

EP Vantage

Bristol-Myers Squibb

Flag link:

Go or no go? Oncology dominates upcoming decisions

Go or no go? Oncology dominates upcoming decisions

EP Vantage

prostate cancer

Bristol-Myers Squibb

Flag link:

#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions

#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions

Endpoints

Flag link:

Lantern files for IPO to study 5-time phase 3 cancer failure

Lantern files for IPO to study 5-time phase 3 cancer failure

Fierce Biotech

Flag link:

BeiGene reports positive Phase III interim analysis for lung cancer drug

BeiGene reports positive Phase III interim analysis for lung cancer drug

MedCity News

clinical trials

non-squamous non-small cell lung cancer

Flag link:

AstraZeneca's Imfinzi gets FDA nod to target small-cell lung cancer

AstraZeneca's Imfinzi gets FDA nod to target small-cell lung cancer

Reuters

Small-Cell Lung Cancer

Flag link:

First of its Kind “Universal” Immune Cell Cancer Therapy

First of its Kind “Universal” Immune Cell Cancer Therapy

Xtalks

prostate cancer

Cardiff University

Flag link:

BeiGene lung cancer treatment meets main goal in late-stage study

BeiGene lung cancer treatment meets main goal in late-stage study

Reuters

clinical trials

Flag link:

The three biggest challenges in lung cancer, and how researchers are tackling them

The three biggest challenges in lung cancer, and how researchers are tackling them

Pharmaforum

Lung Ambition Alliance

Flag link:

Bankrupt uBiome sells off patents, data for $7M; J&J buys options on Pulmatrix's lung cancer drugs

Bankrupt uBiome sells off patents, data for $7M; J&J buys options on Pulmatrix's lung cancer drugs

Endpoints

Flag link:

Spectrum Pharma Shares Slump After Lung-Cancer Drug Doesn't Meet Phase II Endpoint

Spectrum Pharma Shares Slump After Lung-Cancer Drug Doesn't Meet Phase II Endpoint

TheStreet.com

Spectrum Pharma

clinical trials

non-small cell lung cancer

Flag link:

Upcoming events – Axsome’s depression data and Eli Lilly’s IL-10 in lung cancer

Upcoming events – Axsome’s depression data and Eli Lilly’s IL-10 in lung cancer

EP Vantage

Axsome Therapeutics

treatment-resistant depression

Flag link:

Regeneron defends bid to challenge Merck in lung cancer

Regeneron defends bid to challenge Merck in lung cancer

Biopharma Dive

immuno-oncology

Flag link:

Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results?

Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results?

Motley Fool

Bristol-Myers Squibb

Flag link:

Triple meeting – Mirati avoids the worst-case scenario

Triple meeting – Mirati avoids the worst-case scenario

EP Vantage

Mirati Therapeutics

colorectal cancer

Flag link:

Pages